Loading
TG Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Aug 2023.
TG Therapeutics, Inc.: what insiders have been doing
Headquartered in New York City, United States, TG Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 5 insiders have disclosed 10 filings since 18 October 2025.
All open-market trades in the period are sales: 2 sales worth €378k, by 2 insiders, with no purchase on record. At €236k, the sale published on 14 September 2026 by Charney Laurence N is the largest of the period (0.0031% of market cap).
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 10 filings here. Our records for TG Therapeutics, Inc. go back to 2016, with 2 purchases and 17 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 616.3 m USD and net income at 447.2 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
65
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€8M
17 ops. · all time
Who traded when
BuySaleLaurence N. Charney2 sales
Sagar Lonial2 sales
Yann Echelard2 sales
Sean A. Power1 sale
Analyst consensus: bullish or bearish?
Analysts rate TG Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$69.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,152 of 24,148 companies
68.5
score / 100
Value52
Quality85
FCF yld-0.3%
Earn yld5.2%
EV/EBITDA·
ROE100%
Gross mgn84%
Net mgn73%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$56.00
Analyst consensus
7 analystsStrong buy
US$21.00Target US$69.71(+24%)US$86.00
Income statement
RevenueUS$616.3M
Gross profitUS$515.6M84% margin
EBITDAUS$134.4M22% margin
Net incomeUS$447.2M55.2% margin
Valuation
PER (trailing)20.4x
PER (forward)20.7x
P/Book13.2x
Beta1.80
Balance sheet & cash
Market capUS$8.6B
Total debtUS$253.7M
Free Cash Flow-US$25M
Debt / Equity125%
Profitability & ownership
ROE100.3%
ROA7.3%
% insiders7.5%
% institutions74.7%
Last declaration on 14 September 2026
Declarations65 total
5,000 shares@ US$54.960.0031% mcap11.1% of flowCommon StockSEC:0001437749-26-030343:0
5,000 shares@ US$54.95880.0031% mcap11.1% of flowCommonSEC144:0001959173-26-006866
450 shares0Common StockSEC:0001437749-26-026608:2
5,100 shares0Common StockSEC:0001437749-26-026608:0
500 shares0Common StockSEC:0001437749-26-026608:1
30,000 shares0Common StockSEC:0001437749-26-002439:0
622,000 shares0Common StockSEC:0001437749-26-001016:0
90,000 shares0Common StockSEC:0001437749-26-001015:0
5,000 shares@ US$32.5720.7% of flowCommon StockSEC:0001437749-25-036358:0
3,865,126 shares0Common StockSEC:0001437749-25-033888:0
20,852 shares@ US$32.2434.2% of flowCommon StockSEC:0001437749-25-028952:0
21,408 shares0Common StockSEC:0001437749-25-020545:0
14,718 shares0Common StockSEC:0001437749-25-020543:0
14,718 shares0Common StockSEC:0001437749-25-020541:0
14,718 shares0Common StockSEC:0001437749-25-020540:0
14,718 shares0Common StockSEC:0001437749-25-020546:0
62,459 shares0Common StockSEC:0001437749-25-008284:0
6,000 shares0Common StockSEC:0001437749-25-007052:0
750,000 shares0Common StockSEC:0001437749-25-002292:0
87,500 shares0Common StockSEC:0001437749-25-002290:0
11,337 shares@ US$30.2948.0% of flowCommon StockSEC:0001437749-25-000662:0
25,000 shares@ US$30.19533.3% of flowCommon StockSEC:0001437749-24-034595:0
5,000 shares@ US$30.448.5% of flowCommon StockSEC:0001437749-24-034597:0
20,000 shares@ US$24.4865.9% of flowCommon StockSEC:0001437749-24-033950:0
22,250 shares0Common StockSEC:0001437749-24-020848:0
25 of 65 declarations
About TG Therapeutics, Inc.
TG Therapeutics, Inc. (ticker: TGTX) is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States. The company is best understood as a specialty pharma / commercial biotech focused on B-cell–mediated diseases, with its strategic center of gravity in relapsing forms of multiple sclerosis. TG Therapeutics was founded in 1993, originally incorporated as Atlantic Pharmaceuticals, Inc., and its executive offices are in New York City, giving it a clear U.S. capital-markets profile. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/index.php/static-files/d48d6e88-4512-43c0-be01-f8c7d04c6719?utm_source=openai))
The company’s lead asset is BRIUMVI® (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for adults with relapsing forms of multiple sclerosis. BRIUMVI is the main commercial driver of the business and the key asset supporting TG Therapeutics’ transition from development story to revenue-generating company. TG Therapeutics has also developed TGR-1202, an oral PI3K-delta inhibitor, although the investment case is primarily anchored in BRIUMVI commercialization and any potential lifecycle expansion programs. Recent company communications also highlight work on subcutaneous formulations and other pipeline opportunities, suggesting a broader effort to extend the product franchise over time. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/node/17521/pdf?utm_source=openai))
Read moreShow less
From a competitive standpoint, TG Therapeutics operates in a crowded MS treatment landscape dominated by large multinational pharmaceutical companies and established anti-CD20 therapies. Its differentiation depends on clinical profile, physician adoption, payer access, and execution in a market where neurologists have multiple treatment options. Because the company is relatively focused, the equity story is more concentrated than that of diversified pharma peers: upside is driven by commercial scaling, while downside sensitivity remains tied to regulatory execution, reimbursement, and competitive responses. That concentration increases risk, but it also gives investors a clearer line of sight into the core value driver. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-commercial-launch-briumvitm?utm_source=openai))
Geographically, TG Therapeutics is primarily U.S.-focused, but it also has international exposure through ex-U.S. commercialization and partnerships for BRIUMVI in Europe and the United Kingdom. Recent disclosures show that the company reported $616.3 million of total revenue in 2025, including $594.1 million of U.S. net product revenue from BRIUMVI, and it guided 2026 total global revenue to approximately $875–900 million. For investors, that signals a business that has entered a more mature commercialization phase, even though execution risk, regulatory obligations, manufacturing reliance, and competitive pressure remain important considerations. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/press-releases?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
